白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2009年
10期
609-611,615
,共4页
王华庆%邱立华%钱正子%李维%孟祥睿%侯芸%宋拯%赵静%崔秀珍%郝希山
王華慶%邱立華%錢正子%李維%孟祥睿%侯蕓%宋拯%趙靜%崔秀珍%郝希山
왕화경%구립화%전정자%리유%맹상예%후예%송증%조정%최수진%학희산
淋巴瘤%非霍奇金%氟达拉滨%吡柔比星
淋巴瘤%非霍奇金%氟達拉濱%吡柔比星
림파류%비곽기금%불체랍빈%필유비성
Lymphoma,non-Hodgkin%Fludarabine%Piranubicin
目的 探讨Fr(氟达拉滨及吡柔比星)方案治疗复发难治惰性非霍奇金淋巴瘤(NHL)的有效性和安全性.方法 复发难治惰性NHL40例,采用FT方案化疗,28 d为1个周期,共6个周期.FND(氟达拉滨、米托蒽醌及地塞米松)方案治疗惰性NHL的数据为对照.结果 FT组40例共治疗228个周期,有效率62.5%,中位无进展生存期超过20个月,2年总生存率70.0%,与对照组相似(P>0.05);不良反应以中性粒细胞减少(80.0%)最为常见,但Ⅲ～Ⅳ度中性粒细胞减少症和肺炎的发生率均低于对照组,分别为12.5%、29.0%和2.5%、23.0%(P<0.05).结论 FT方案治疗复发难治惰性NHL安全有效,骨髓抑制轻,感染发生率低.
目的 探討Fr(氟達拉濱及吡柔比星)方案治療複髮難治惰性非霍奇金淋巴瘤(NHL)的有效性和安全性.方法 複髮難治惰性NHL40例,採用FT方案化療,28 d為1箇週期,共6箇週期.FND(氟達拉濱、米託蒽醌及地塞米鬆)方案治療惰性NHL的數據為對照.結果 FT組40例共治療228箇週期,有效率62.5%,中位無進展生存期超過20箇月,2年總生存率70.0%,與對照組相似(P>0.05);不良反應以中性粒細胞減少(80.0%)最為常見,但Ⅲ～Ⅳ度中性粒細胞減少癥和肺炎的髮生率均低于對照組,分彆為12.5%、29.0%和2.5%、23.0%(P<0.05).結論 FT方案治療複髮難治惰性NHL安全有效,骨髓抑製輕,感染髮生率低.
목적 탐토Fr(불체랍빈급필유비성)방안치료복발난치타성비곽기금림파류(NHL)적유효성화안전성.방법 복발난치타성NHL40례,채용FT방안화료,28 d위1개주기,공6개주기.FND(불체랍빈、미탁은곤급지새미송)방안치료타성NHL적수거위대조.결과 FT조40례공치료228개주기,유효솔62.5%,중위무진전생존기초과20개월,2년총생존솔70.0%,여대조조상사(P>0.05);불량반응이중성립세포감소(80.0%)최위상견,단Ⅲ～Ⅳ도중성립세포감소증화폐염적발생솔균저우대조조,분별위12.5%、29.0%화2.5%、23.0%(P<0.05).결론 FT방안치료복발난치타성NHL안전유효,골수억제경,감염발생솔저.
Objective To evaluate the efficacy and safety of fludarabine and pirarubicin (FT) regimen in the treatment of refractory or relapsed indolent non-Hodgkin lymphoma (NHL). Methods A total of 40 patients with relapsed or refractory indolent NHL were treated with FT regimen, one cycle for 28 days, total 6 cycles. The data of indolent NHL patients treated with fludarabine, noventrene and dexamethasone (FND) regimen were collected as control. Results 40 patients were given 228 cycles chemotherapy, overall response rate was 62.5 %, median progression-free survival was more than 20 months and 2 years overall survival rate was 70.0 %. The main toxicities was leucopenia (80.0 %), but the incidence of WHO Ⅲ-Ⅳ leucopenia and pneumonia was less than that of in the control group, the rate were 12.5 % vs 29.0 % and 2.5 % vs 23.0 % respectively (P <0.05). Conclusion The efficacy of FT regimen was as good as FND regimen, but the incidence of leucopenia and pneumonia by Ⅲ-Ⅳ was lower in FT group than in FND group. So the FT regimen was an effective and safe second-line salvage regimen for relapsed or refractory indolent non-Hodgkin lymphoma.
